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1. Introduction 
In 2011, the regular increase in survival of childhood cancer (overall survival [OS] 72% at 10 
years) (Berger 2006) suggests that one of every 850 adults in Europe has had pediatric 
cancer. As these children become adults, their concerns with possible long-term disease 
complications and risks associated with therapy received increase. Adverse effects of cancer 
therapies include disorders of the endocrine system, cardiac and pulmonary dysfunction, 
renal and hepatic impairment, secondary malignant disease, and psychosocial difficulties. 
Significant deliberation must also be given to the potential effects of a treatment regimen on 
the future fertility of pediatric patients with cancer. We review the literature regarding 
fertility and chemical risk factors for hypofertility in these patients to increase awareness of 
and avoid long-term clinical consequences of chemical therapies. 
2. Gonadic toxicity  
Gonadic toxicity results from systemic chemotherapy or irradiation of the spinal axis, pelvis, 
or entire body. 
In boys, toxicity affects the somatic cells, i.e., the Sertoli and Leydig cells and germinal 
lineage. Sertoli cells assure the support, nutrition, and protection of germ cells, synthetizing 
numerous proteins, including inhibin and androgen-binding protein (ABP), and Leydig cells 
secrete testosterone. Chemotherapeutic toxicity primarily involves spermatogenesis, rise in 
follicle-stimulating hormone (FSH), and decline in inhibin.  
Anti-Müllerian hormone (AMH) is the earliest Sertoli cell-specific protein expressed by the 
male gonad and is secreted by the testes from the eighth week of gestation and at high levels 
until puberty, when its decreasing production characterizes maturation of the Sertoli cells. 
The decline in AMH expression during puberty coincides with increased androgen secretion 
by Leydig cells and is considered a clear marker of the elevated intratesticular androgen 
concentration that inhibits AMH production by Sertoli cells at this time. The high level of 
AMH production before puberty allows its measurement to serve as a reliable marker for 
the presence of testicular tissue in childhood, when testosterone levels are very low. 
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Chemotherapy alone does not alter Leydig incapacity, as evidenced by a normal secretion of 
testosterone and declining levels of AMH during puberty. Puberty occurs normally even if 
involvement of the germinal lineage decreases testicular volume (A La Marca 2010). 
Although female reproduction requires a functioning hypothalamic-pituitary-gonadal axis, 
ovaries, and uterus, reproductive potential in women is mainly limited by available oocytes. 
The process of oogenesis begins before birth with a peak in oocyte number (6 to 7 million) at 
20 weeks’ gestation followed by progressive atresia and drop in number of oocytes to one to 
2 million at birth and 300,000 at puberty. Oocytes remain arrested as primordial follicles 
until puberty, a stage postulated to be less sensitive to gonadotoxins. At the initiation of 
puberty, a monthly cohort of follicles is recruited, one becomes dominant, and the others 
undergo atresia. Accelerated atresia coincides with a decrease in the quantity and quality of 
oocytes, raising the risk of infertility, aneuploidy, and spontaneous miscarriage. A rise in 
serum FSH often indicates accelerated atresia and impending ovarian failure. Before age 40 
years, persistent FSH concentrations above 30 IU/L in the setting of amenorrhea, regardless 
of inciting events, suggest a diagnosis of premature ovarian failure (Rebar 2009).  
Levels of anti-Müllerian hormone may represent the ovarian pool and could be a useful 
marker of ovarian reserve (A La Marca 2010). AMH is produced and secreted into the 
circulation by the gonads and can be measured in the serum of men and women. 
Nonsignificant variations in AMH levels have been reported throughout the menstrual 
cycle. In women, AMH levels seem to be unmodified under conditions in which 
endogenous gonadotropin release is subtantially diminished, such as during pregnancy, 
treatment with gonadotropin-releasing hormone (GnRH) agonist, and short-term oral 
contraceptive administration, indicating that non-cyclic FSH-independent ovarian activity 
persists even when pituitary FSH secretion is suppressed. However, sometimes damage to 
the ovarian reserve cannot predict ability to conceive.  
Lie Fong and associates compared serum AMH levels in 185 adult female survivors of 
childhood cancer (excluding brain tumors) and 42 control subjects. Median follow-up was 18.1 
years (range, 4.1 to 43.2 years). Median AMH concentrations were not significantly different 
between the analyzed cohort (1.7 g/L) and controls (2.1 g/L). However, in 27% of survivors, 
AMH levels were lower than the tenth percentile of normal values, and in 43%, they were 
lower than 1.4 g/L, a previously established cut-off value for predicting ongoing pregnancy 
after assisted reproduction. AMH levels did not differ significantly in subgroups classified 
according to disease but were significantly lower in survivors who underwent 3 or more cycles 
of chemotherapy containing procarbazine than in controls (median 0.5 g/L). AMH levels 
were also significantly lower in survivors who had been treated with abdominal or total body 
irradiation than in controls (median < 0.1 g/L). AMH can be used to identify subgroups of 
survivors of childhood cancer who are at risk for decreased fertility or premature ovarian 
failure. In these survivors with high risk of hypofertility, the capacity for fertility preservation 
should be considered prior to starting assisted reproductive treatment because they may have 
a poor chance of achieving or maintaining pregnancy after treatment (Lie Fong 2009).  
3. Which chemotherapies contribute to decline in fertility? 
Alkylating agents, including cyclophosphamide, ifosfamide, chlormethine, busulfan, 
melphalan, procarbazine, and chlorambucil, are the primary chemotherapies that carry a 
high risk for gonadic dysfunction (Wallace 2005). 
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Boys frequently experience a passing rise in luteinizing hormone (LH) with azoospermia in 
the period just after receiving chemotherapy (2 to 8 years). In a series of patients affected by 
non-Hodgkin lymphomas, Pryzant describes an 83% recovery of spermatogenesis in 
patients receiving less than 9.5 g/m2 of cyclophosphamide compared to 43% recovery in 
those receiving a higher dose (Pryzant 1993). A reduction of cyclophosphamide dose to less 
than 7.5 g/m2 is associated with up to 70% conservation of fertility in survivors of Ewing’s 
sarcoma. 
A recent study including 6224 survivors aged 15 to 44 years who were not surgically sterile 
found a decline in fertility in men who had received childhood doses of procarbazine 
greater than 4.2 g/m2 or  cyclophosphamide greater than 9.3 g/m2. Those who received 
cytarabine were more likely to ever sire a pregnancy than those who were not exposed to 
this agent. There is no clear explanation of this observation. The likelihood of siring a 
pregnancy was greater for men whose cancer was diagnosed and treated before age 4 years 
than those diagnosed between 15 and 20 years and did not differ for those diagnosed 
between 5 to 9 years or 10 to 14 years relative to those 15 to 20 years (Green 2010). 
Cyclophosphamide administration has been associated with impaired spermatogenesis after 
treatment of children for nonmalignant and malignant disease. Azoospermia has been 
reported after cumulative cyclophosphamide doses as low as 6 g/m2 (Kenney 2001). In 
survivors of osteosarcoma, there is an implied risk of azoospermia from ifosfamide, with 
doses between 42 and 60 g/m2 (Longhi 2003). 
Byrne and colleagues evaluated fertility in male long-term survivors of acute lymphoblastic 
leukemia (ALL) diagnosed during childhood (Byrne 2004). Mean age at diagnosis was 10.9 
years, and average age at interview was 22.8 years. Controls were siblings (average age, 24 
years). Only 33% of male survivors had married or had a live-in relationship compared to 
49% of male controls, and though the age in each group was similar for first fathering a 
pregnancy, fewer survivors than controls had become fathers. The relative risk (RR) for 
fertility was 0.80 for survivors aged 18 to 21 years when they first sired a pregnancy 
compared with sibling controls and 1.02 for survivors older than 21 years at the time they 
first sired a pregnancy. Men who received cranial radiotherapy (RT) without spinal RT 
before age 9 were less likely to become fathers than controls; their fertility was only 9% that 
of controls. 
Ovarian function may be impaired after chemotherapy that includes an alkylating agent, 
such as nitrogen mustard, procarbazine, chlorambucil, or cyclophosphamide. The risk of 
ovarian failure appears to correlate directly with cumulative dose but inversely with age at 
exposure (Schilsky 1981, Andrieu 1983). Six cycles of combined nitrogen mustard, 
vincristine, procarbazine, and prednisone expose a patient to 8.4 g/m2 of procarbazine and 
72 mg/m2 of nitrogen mustard. Such therapy carries a high risk of premature ovarian failure 
that may lead to precocious menopause. Green examined the fertility status of 5149 female 
survivors of childhood cancer aged 15 to 44 years who were not surgically sterile and noted 
that fertility decreased with increasing doses received of lomustine (CCNU) (from 360 
mg/m2) or cyclophosphamide (from 3.7 g/m2). A low risk of pregnancy was also associated 
with increasing doses received of alkylating agents, such as those administered for Ewing’s 
sarcoma (8.4 g/m2 of cyclophosphamide and 63 g/m2 of ifosfamide) (Green 2009). 
Chemotherapies administered before autologous stem cells that include high doses of 
alkylating agents, such as the busulfan (600 mg/m2) or melphalan, are a very important 
cause of premature ovarian failure (Teinturier 1998). 
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Byrne’s group reported a significantly lower unadjusted fertility rate for female survivors of 
ALL than their siblings but could not demonstrate an effect of treatment with an alkylating 
agent or spinal irradiation on fertility rates (Byrne 2004). 
4. Fecundity of survivors of childhood cancer 
Fecundity, the capacity for producing offspring, is affected by various factors, including 
marital status, emotional disorders, endocrine or neurological disorders, and others. 
A recent Italian study analyzes the marital (or living in couples) status of survivors of 
childhood cancer and compares it to that of the general Piedmontese population. At an 
average age of 28 years, 75% of survivors are not in couples, but the proportion is 
reversed after age 40 years, with 75% living in couples. On average, the wedding rate of 
survivors of childhood cancer is 32% lower than that of the general population for men 
and 18% lower for women. The discrepancy is very sharply marked for survivors of brain 
tumors, who are affected by endocrine and neurological complications as well as 
emotional disorders (Dama 2009).  
For the Childhood Cancer Survivor Study, 20,720 patients were eligible for study, 17,561 
questionnaires were sent (3159 lost to follow-up), and 3209 patients declined participation. 
At contact, 12,220 were aged 15 to 44 years (female, 5665; male, 6555). Five hundred and 
sixteen female survivors were surgically sterile, and 1372 indicated they had been pregnant 
5 or more years after the date of their primary cancer diagnosis. Female survivors of the 
CCSS cohort were less likely than their sibling cohort to become pregnant (relative risk for 
survivors of ever being pregnant was 0.81 compared with female siblings). Pregnancy was 
more likely among those who had completed less than a high school education or were 
African American or married, findings that reflected the general population, or those in the 
youngest group at diagnosis (Green 2009). 
We are conducting a study of fertility and quality of life of women treated in France for 
childhood cancer (except ALL) between 1948 and 1992 and sent 1261 survivors a self–
assessment questionnaire that included an SF36 quality-of-life survey and questions on 
social outcomes, health, family, and fertility. Of 944 (75%) who answered, 489 had conceived 
at least one child, 29 adopted, and 94 could not bear a child despite their desire. There was 
no significant difference in quality of life between women with at least one child and 
women without children. By itself, the mental score of the SF36 appeared to correlate with 
growth deficiency, locomotive and psychological late effects, and age at diagnosis but did 
not correlate with initial tumor, gonadic deficiency, or fertility; the physical score correlated 
with neither fertility nor gonadic insufficiency. So, the SF36 findings seemed to indicate that 
the hypofertility experienced by patients treated for childhood cancer did not alter their 
quality of life. Future study could refine the psychological, social, and professional profile 
(personal data). 
5. Knowledge of fertility? 
The varied nature of gonadal insult after chemo- or radiotherapy often makes it difficult to 
predict whether treatment a patient is about to undergo will impair fertility. However, 
Wallace has proposed a classification of subfertility risk according to type of malignant 
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disease and associated treatment (Table 1) (Wallace 2005), and protocols for malignant 
disease are continually evolving to improve survival and reduce late effects, as seen, for 
example, in the intensification of treatment for ALL but less intensive management of 
Hodgkin disease over the last 10 years.  
 
Low risk (< 20%) 
Acute lymphoblastic leukemia 
Wilm’s tumor 
Soft tissue sarcoma: stage I 
Germ-cell tumors (with gonadal preservation and no radiotherapy) 
Retinoblastoma 
Brain tumor:  surgery only, cranial irradiation < 24 Gy 
 
Medium risk  
Acute myeloblastic leukemia (difficult to quantify) 
Hepatoblastoma 
Osteosarcoma 
Ewing’s sarcoma nonmetastatic 
Soft tissue sarcoma:  stage II or III 
Neuroblastoma 
Non-Hodgkin lymphoma 
Hodgkin’s disease:  alternating treatment 
Brain tumor:  craniospinal radiotherapy, cranial irradiation > 24 Gy 
 
High risk (> 80%) 
Whole-body irradiation 
Localized radiotherapy:  pelvic or testicular 
Chemotherapy conditioning for bone marrow transplantation 
Hodgkin’s disease:  treatment with alkylating drugs 
Soft tissue sarcoma:  stage IV (metastatic) 
Ewing’s sarcoma:  metastatic 
Table 1. Best assessment of risk of subfertility after current treatments for common cancers 
in childhood and adolescence (Wallace 2005) 
A study in California (Zebrack 2004) noted that 59% of young adult survivors of childhood 
cancer from Los Angeles do not know whether they will be fertile. More than half indicate 
that neither their relatives nor doctors spoke to them of potential consequences of 
treatments received during the care of their cancer. Others received vague information 
concerning risks. Such findings suggest that health care providers who come into contact 
with long-term survivors of childhood cancer need to be prepared to provide them with 
accurate information about potential reproductive problems and risks for infertility based 
upon knowledge of their past treatment. 
Van den Berg sent short questionnaires to parents of 159 male survivors of childhood cancer 
diagnosed and treated with chemotherapy in the Emma Children Hospital of Amsterdam 
(Van den Berg 2008), inquiring about year of birth, age at initial diagnosis, type of 
malignancy, and whether there was relapse. The remaining questions asked whether 
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information given at initial diagnosis included discussion of possible secondary infertility, if 
sperm was analyzed after treatment in pubertal boys, and if the parents expected their child 
to be infertile. Questionnaires were returned by 63%. Of these, 50% of parents recalled 
statements concerning an effect on fertility, 36% indicated that this had not been the case, 
and the remainder were unsure. Sperm analysis had been performed after treatment in 4 
cases and semen collected prior to start of therapy in 14 cases; in 2 cases, the parent was 
uncertain in this regard. Nine percent of parents thought their son’s infertility was a fact, 
31% expected normal fertility, and 60% were uncertain.  
Actual infertility influences not only procreation; even the suspicion of its risk profoundly 
affects body image, dating, and marriage (Schover 1999, Byrne 1989, Thaler-DeMers 2001, 
Zevon 1990). In long-term survivors of childhood cancer, at least 53% of men and 65% of 
women worry whether they can have children (Langeveld 2003). Limited knowledge of the 
effects of their treatment from inadequate processing of information given at diagnosis or 
failed memory of its content is a major contributing factor to these concerns. Parents are 
often an important source of information when a child suffers from a malignancy, and as 
children grow older, parents give them age-specific information. Data in this study indicate 
that despite the medical teams’ certainty that parents were informed, half the parents could 
not recall receiving information concerning fertility. Care providers and/or parents might 
also withhold such information. Half the care providers stated that it is inappropriate to 
provide this information at the time consent is being given for treatment, considering it 
more important to offer information about fertility when therapy is finished (Goodwin 
2007). The literature indicates that at least part of the poor recall of survivors of childhood 
cancer regarding issues of fertility is that the information was not provided by health care 
workers. Other contributing factors include the turmoil of unexpected events in the first 
weeks of illness in a case of childhood malignancy that often overloads parents with 
information on subjects with which they are unaccustomed and their withholding of 
information to shield their child from future burden or to avoid the child’s reaction. It is 
highly recommended that medical providers check whether parents have received adequate 
information on their child’s future fertility after they have had time to cope with the 
problems and emotions at initial diagnosis or relapse. 
6. Fertility preservation 
6.1 Male patients 
Semen cryopreservation is an established and successful technique for men, and though its 
value has been shown in adolescent patients, it may be difficult to achieve. Treatment of 
malignant pediatric disease should be started as soon as possible after diagnosis, but 
teenagers at this early point in the disease process might be too distressed to discuss fertility 
and subsequently unlikely to produce a semen sample. Discussions should be dealt with 
sensitively in language understood by the patient. As well, it is important that sperm 
banking be practiced near pediatric oncology centers. 
Boys sufficiently mature might produce semen samples by masturbation, or penile vibratory 
stimulation or rectal electrostimulation under anaesthetic can be considered if this method is 
not possible (Schmiegelow 1998). Alternatively, if spermatogenesis is established, sperm can 
be retrieved after testicular or epididymal aspiration. 
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Methods of storing sperm have improved significantly, and technological advances in 
assisted reproductive technology using intracytoplasmic sperm injection (ICSI) increase the 
likelihood of successful pregnancies using banked sperm. 
Prepubertal boys pose additional challenges for fertility preservation because they cannot 
produce semen for cryopreservation. Germline cells of the prepubertal testes include 
spermatogonial stem cells, but mature spermatozoa are not yet present. A novel approach to 
circumvent this problem is cryopreserving the boy’s testicular tissue. When he is ready to 
begin a family years after undergoing cancer treatment, the cryopreserved tissue is thawed 
and the banked germ cells reimplanted into the patient’s testes to enable full maturation and 
reproductive potential (Brinster 2007). Unfortunately, a typical testicular biopsy contains 
insufficient numbers of stem cells to restore fertility, and a large supply of stem cells is 
required to ensure that no remaining cancer cells contaminate the transplanted cell 
population. Therefore, culturing methods must be developed to remove unwanted cancer 
cells and increase the number of biopsied stem cells to restore fertility through 
autotransplantation procedures. A novel approach is to employ a cryopreserved testicular 
sample to enrich for spermatogonial stem cells that are subsequently matured into viable 
spermatids in vitro through innovative culturing procedures. Use of this strategy could then 
achieve fertilization by ICSI (Ginsberg 2009).  
6.2 Female patients 
Oocyte cryopreservation is a feasible method of fertility preservation for young girls. 
Oocytes are fragile, and ovarian tissue consisting of germ cells can be removed and stored 
before gonadotoxic treatment. The ovarian cortex is utilized because it is rich in primordial 
follicles (Poirot 2002-2007). After the patient is cured, this tissue might be either returned to 
the patient via autotransplantation or matured in vitro to produce offspring by in vitro 
fertilization, similar to the technique proposed for male patients at this age. In vitro 
maturation is highly desirable because it obviates the concern of reimplanting cancer cells 
into the patient. Accordingly, the development of methodologies for obtaining human 
oocytes from primordial follicles is undergoing intensive laboratory investigation (Smitz 
2010). However, ovarian transplantation may not be indicated in female patients with 
blood-borne malignancy because cancer cells circulating within the blood could remain in 
cryopreserved ovarian tissues (Dolmans 2010). Because ovarian biopsy is invasive and 
experimental, this option should only be considered for female patients at high risk of 
infertility. The most appropriate pediatric female candidates are patients undergoing stem 
cell transplantation, in whom there is a high likelihood of acute ovarian failure. In contrast, 
pediatric patients with cancer exposed to high doses of alkylating agents as part of their 
chemotherapy regimen, who often have a window of fertility following treatment and are 
more prone to premature ovarian failure, may have the opportunity as adults to undergo 
successful fertility preservation interventions. 
Thus , ovarian cryopreservation, including transplantation, is now a clinical option available 
for children. Transplanted frozen/thawed tissue may be highly effective in restoring 
ovarian function and maintain function for prolonged periods of time. The many follicles 
present in children’s ovaries could be used to induce puberty and possibly provide fertility 
later on. Although tissue can be transplanted to restore fertility, this method’s efficacy is 
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limited and requires refinement. Results are encouraging for continued research efforts and 
may have far reaching possibilities that we must begin to address. Current research focuses 
on the possibility of hormonal protection of the gonad, long-term storage of testicular or 
ovarian material, and xenotransplantation into a host species. Transplanted material may 
subsequently be reintroduced into the patient, or gametes may be extracted for assisted 
reproductive techniques, such as in vitro fertilization. 
7. Offspring among survivors of childhood cancer 
7.1 Low birth weight in offspring after pelvic irradiation  
One CCSS study included 1915 females who reported 4029 pregnancies (63% live births, 1% 
still4births, 15% miscarriages, 17% abortions, 4% unknown or in gestation). Pregnancy 
outcome did not differ significantly by treatment. There was a higher, but not statistically 
significant, risk of miscarriage among women whose ovaries were in the field of radiation 
therapy (RR = 1.86, P = 0.14), near the field (RR = 1.64, P = 0.06), or shielded (RR = 0.90, P = 
0.88). The rate of live birth was not lower for patients treated with any particular 
chemotherapeutic agent. The offspring of patients who received pelvic irradiation were 
more likely to weigh less than 2500 g at birth (RR = 1.84, P = 0.03). This large study did not 
identify adverse pregnancy outcomes for female survivors treated with most 
chemotherapeutic agents but did indicate that the offspring of women who received pelvic 
irradiation are at risk for low birth weight (Green 2002). 
7.2 No genetic anomalies among offspring 
Drugs used to treat cancer are designed to interfere with DNA, cell division, and cellular 
metabolism, processes essential to embryogenesis and fetogenesis. A cohort study described 
by Byrne and associates (Byrne 1998) found genetic anomalies in 3.2% of 2198 offspring of 
survivors of childhood cancer compared to 3.1% in controls (4544 newborns). Similar results 
are reported in a Danish cohort (Winther 2004). Thus, there appear to be no genetic 
anomalies in offspring of survivors who underwent chemotherapy for childhood cancer. 
7.3 Congenital anomalies among offspring 
The large series described by Byrne (Byrne 1998) found congenital anomalies in 3.4% of 2198 
offspring of childhood survivors compared to 3.1% in controls.  Similarly, an international 
study (United States and Denmark) described by Boice and associates found no significant 
difference in relative risk of congenital anomalies among offspring of 25,000 survivors of 
childhood cancer who either fathered or gave birth to around 6000 children compared with 
their sibling controls (Boice 2003). Hawkins also reported only 46 congenital anomalies in 
1033 (4.4%) newborns of cancer survivors, which is similar with the general population 
(Hawkins 1988). 
However, an increased risk of congenital anomalies has been reported in the offspring of 
female survivors of cancer previously diagnosed with Wilms’ tumor and treated with flank 
radiation. The mechanism underlying this risk has not been identified but may involve 
radiation damage to the female gamete (Green 2002 JCO) 
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7.4 No excess risk of cancer among offspring 
In the Nordic cohort, including 14,652 survivors of cancer in childhood or adolescence 
diagnosed since the 1940s and 1950s, only 22 sporadic cancers, excluding retinoblastoma 
(17 cases) and other hereditary cancers, were observed among 5847 offspring. The 
standardized incidence ratio is 1.3 (95% confidence interval [CI], 0.8 to 2.0). No neoplasms 
were observed among the children of survivors of leukemia, neuroblastoma, or hepatic 
tumors. The overall standardized ratio for nonretinoblastoma neoplasms was 3.9 (95% CI, 
2.1 to 6.7) for offspring whose parents were younger than 10 years at diagnosis and 1.1 
(95% CI, 0.6 to 1.8) for those with parents diagnosed at age 10 or older. All but one 
offspring with cancer were born at least 8 years after cancer was diagnosed in their 
mother (Sankila 1998). 
There seems to be no increase in childhood malignancies in offspring of survivors, with the 
exception of cancers arising as a result of inherited syndromes, including familial 
adenomatous polyposis, hereditary nonpolyposis colon cancer, retinoblastoma, Li-Fraumeni 
syndrome, and others. 
7.5 No modification of sex ratio 
Some researchers have assessed the sex ratio of fetuses born to cancer survivors after 
treatment compared with the general population and noted no difference, ensuring that 
cancer treatment does not increase incidence of X-linked mutations (Winther 2003) 
8. Conclusion 
Infertility is an important issue arising as a late effect of childhood cancer treatment and 
should be discussed at initial cancer diagnosis if therapy may carry some risk. Although the 
topic may be difficult for parents, it is necessary to consider some method of protecting 
fertility at an early stage, even in young children. Although it is very difficult to predict 
fertility after treatment, there is much interest in potential markers of gonadal damage that 
can be used in adolescents and young adults. 
Beyond the possible precautionary measures in assessing issues surrounding fertility in 
survivors of childhood cancer, it is necessary to review the history of the patient’s disease 
and treatment regimen, clarifying chemotherapies, surgeries, and irradiation, and biologic 
markers may also be measured (FSH, testosterone, estradiol, AMH). Knowledge of these 
data will elucidate how to care better for the patient, and if there is a risk to fertility, a 
couple can be referred for consultation with a health center for assisted reproduction. 
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